360dx7h
Roche IHC Assay Nabs CE Mark as Companion Diagnostic for Abbvie's Elahere in Ovarian Cancer
The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.
Daily9h
AbbVie gets European Commission nod for Elahere for Platinum-Resistant ovarian cancer
AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...
GlobalData on MSN10h
Roche secures CE mark for ovarian cancer detection test
Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...
Pharmabiz18h
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...